The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs

BackgroundTP53 mutation is a poor factor for non-small cell lung cancer (NSCLC), while the effect of TP53 on prognosis in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD) with brain metastasis remains elusive and needs further exploration.MethodsWe retrospectively analyzed...

Full description

Bibliographic Details
Main Authors:	Weiguo Gu, Penghui Liu, Jiaming Tang, Jianfei Lai, Siya Wang, Jiaming Zhang, Jinbiao Xu, Jianxiong Deng, Feng Yu, Chao Shi, Feng Qiu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	lung cancer brain metastasis EGFR TP53 prognosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1288468/full

Similar Items

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

Concordance of Abundance for Mutational <i>EGFR</i> and Co-Mutational <i>TP53</i> with Efficacy of <i>EGFR</i>-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
by: Youping Wang, et al.
Published: (2023-09-01)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
by: Cefan Zhou, et al.
Published: (2022-08-01)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
by: Surui Liu, et al.
Published: (2022-04-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
by: John Wen‐Cheng Chang, et al.
Published: (2023-02-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

The EGFR-TMEM167A-p53 Axis Defines the Aggressiveness of Gliomas
by: Berta Segura-Collar, et al.
Published: (2020-01-01)

Study of the expression of oncoprotein p53, EGFR in colorectal carcinomas with different proliferative activity
by: I.S. Shponka, et al.
Published: (2023-04-01)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
by: Tzu-Hsuan Chiu, et al.
Published: (2021-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023-12-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
by: Shiyu Li, et al.
Published: (2022-12-01)

Third generation EGFR TKIs: current data and future directions
by: Chee-Seng Tan, et al.
Published: (2018-02-01)

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
by: Kai Shang, et al.
Published: (2022-12-01)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
by: Chaido Sirinian, et al.
Published: (2021-10-01)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer Cells
by: Chia-Chi Hsu, et al.
Published: (2021-01-01)

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort
by: J. Machado-Rugolo, et al.
Published: (2023-04-01)

Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs
by: Dongyu Li, et al.
Published: (2023-04-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
by: Di Hu, et al.
Published: (2023-06-01)

<i>TP53</i> Co-Mutation Status Association with Clinical Outcomes in Patients with <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Xiuning Le, et al.
Published: (2022-12-01)

D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy
by: Jonathan Barra, et al.
Published: (2021-07-01)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
by: Xiaoqing Yu, et al.
Published: (2023-03-01)

Dynamic Assessment of Tissue and Plasma <i>EGFR</i>-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs
by: Hsiang-Ling Ho, et al.
Published: (2022-09-01)

The Role of <i>TP53</i> Mutations in <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
by: Matteo Canale, et al.
Published: (2022-02-01)

Treatment Strategies for Non-Small Cell Lung Cancer with Common <i>EGFR</i> Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
by: Julian A. Marin-Acevedo, et al.
Published: (2023-01-01)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
by: Guowei ZHANG, et al.
Published: (2022-09-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
by: XU Wenwen, et al.
Published: (2021-12-01)

Concomitant <i>TP53</i> Mutation Confers Worse Prognosis in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
by: Matteo Canale, et al.
Published: (2020-04-01)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma
by: Qiwen Li, et al.
Published: (2021-04-01)

Evaluation of Light-Emitting Diodes’ Effects on the Expression Level of P53 and EGFR in the Gingival Tissues of Albino Rats
by: Azhar Ghanim Ahmed, et al.
Published: (2019-09-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
by: Yahua Wu, et al.
Published: (2023-12-01)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
by: Chunhong Hu, et al.
Published: (2023-01-01)

Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs
by: Kunchen Wei, et al.
Published: (2023-07-01)

Special Staining and Protein Expression of VEGF/EGFR and P53/NF-κB in Cryptorchid Tissue of Erhualian Pigs
by: Penggang Liu, et al.
Published: (2024-01-01)